Deltex Medical Regulatory News (DEMG)

20 Sep 2005 07:04

Deltex Medical Group PLC20 September 2005 20 September 2005 Deltex Medical Group plc ('Deltex Medical' / 'Company') US Army hospital purchases four CardioQTM monitors for routine use in the management of surgical and trauma patients Deltex Medical Group plc, the AIM listed haemodynamic monitoring company, todayannounces that it has sold four CardioQ monitors and an initial stock ofdisposable oesophageal probes to the William Beaumont Army Medical Center in ElPaso, Texas. The monitors are intended for use in medical and surgical patientsin the intensive care unit and those patients undergoing elective or emergencysurgery in the operating room. Physicians at the hospital are also working tomake the CardioQ an integral part of patient care in a wider range of clinicalapplications, including trauma surgery and neurosurgery. The William Beaumont Army Medical Center provides care for active servicepersonnel and their families and also provides infrastructure and personnel forbattlefield support as required. Andy Hill, Deltex Medical's Chief Executive, commented: "This sale is the result of a recent successful evaluation of the CardioQ inpatients at the William Beaumont Army Medical Center in medical intensive careand in surgery. We are looking forward to working with the anesthesiologists,intensivists, surgeons, and managers at the hospital as they continue toimplement CardioQ-based haemodynamic monitoring as a standard of care." For further information, please contact:- Deltex Medical Group plc 01243 774 837Nigel Keen, ChairmanAndy Hill, Chief ExecutiveEwan Phillips, Finance Director Financial Dynamics 0207 831 3113David Yates / John Gilbert Notes for Editors Deltex Medical manufactures and markets the CardioQ monitor, which usesdisposable ultra-sound probes inserted into the oesophagus to determine theamount of blood being pumped around the body - 'circulating blood volume'.Reduced circulating blood volume is known as hypovolaemia, which leads toinsufficient oxygen being delivered to the organs. This causes medicalcomplications including peripheral and major organ failure which can lead todeath. Hypovolaemia, which is akin to severe dehydration, affects virtuallyevery patient having surgery because of the combined effects of pre-operativestarvation, the impact of the anaesthetic agents and trauma from the surgeryitself. Using fluids and drugs, guided by the CardioQ, to optimise the amountof circulating blood significantly reduces post-operative complications allowingpatients to make a faster, more complete recovery and return home earlier. The CardioQ incorporates the Company's proprietary software and a smalldiameter, easy-to-use, minimally invasive, disposable oesophageal probe that isused for transmitting and receiving an ultra-sound signal. By using thistechnology, the CardioQ provides clinicians with the ability to haemodynamicallyoptimise critically ill patients and those undergoing routine moderate to majorsurgery through the controlled administration of fluid and drugs. Haemodynamicoptimisation has been scientifically proven to improve the speed and quality ofpatient recovery and reduce hospital stay. There are already over 1,250 CardioQs currently in use in hospitals worldwideand distribution arrangements are in place in over 30 countries. In addition,there are currently more than 90 clinical publications on the use of the CardioQwhich have repeatedly:- • validated the results of the Monitor against known standards for measuring cardiac output, demonstrating that the technology works • proved that the CardioQ works in a wide range of surgical procedures • demonstrated that the Company's technology provides significant health and economic benefits by helping to reduce post-operative complications and length of hospital stays by an average of 30 to 40 per cent for a wide range of patients. This information is provided by RNS The company news service from the London Stock Exchange